LIN, SHI-LUNG,林 希龙,林 希龍,WU, DAVID TS,吴堂熙,吳堂熙,LU, HSUAN HSUAN,吕萱萱,呂萱萱,林 希龙,林 希龍
申请号：
TW107106212
公开号：
TW201842923A
申请日:
2018.02.23
申请国别(地区):
TW
年份:
2018
代理人:
摘要：
This invention generally relates to a composition and method of using mam-made small RNAs, such as small interfering RNAs (siRNA), microRNAs (miRNA) and their hairpin-like precursors (pre-miRNA), as tumor suppressing anti-cancer drugs for treating human tumors and cancers, in particular, but not limited, for treating skin (melanoma), blood (leukemia), prostate, breast, liver and lung cancers as well as various neoplastic tumors, such as brain tumors and teratocarcinomas that contain a variety of tumorous and cancerous cells derived from all three germ layers of tissues, including ectoderm, mesoderm and endoderm. More specifically, the present invention relates to the use of miR-302-like siRNA (siR-302) and/or miR-302 precursors (pre-miR-302) for developing novel medicines and therapies against a variety of human cancers, in particular lung cancers.本發明大體上關於使用人造小RNA，諸如小干擾RNA(siRNA)、微RNA(miRNA)及其髮夾型前驅體(pre-miRNA)作為腫瘤抑制抗癌藥之組合物及方法，其用於治療人類腫瘤及癌症，尤其(但不限於)用於治療皮膚癌(黑色素瘤)、血液癌(白血病)、前列腺癌、乳癌、肝癌及肺癌以及各種贅生性腫瘤，諸如含有源自組織之全部三個胚層，包括外胚層、中胚層及內胚層之多種腫瘤細胞及癌細胞之腦腫瘤及畸胎癌。更特定言之，本發明係關於miR-302類siRNA(siR-302)及/或miR-302前驅體(pre-miR-302)用於開發針對多種人類癌症，特別是肺癌之新穎藥物及療法之用途。
